Drug Trial Radar · NCT04586244
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
Jan 14, 2022
Primary completion
Jan 29, 2024
Study completion Jan 29, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.
Conditions
- Urothelial Carcinoma
Interventions
retifanlimabDrug
retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
epacadostatDrug
epacadostat will be administered daily twice daily orally up to and including day of surgery.
INCAGN02385Drug
INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
INCAGN02390Drug
INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in CD8+ Lymphocytes Within the Resected TumorTime frame: up to 69 days
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
University of Cincinnati
Cincinnati, Ohio
Ohio State University Medical Center Division of H
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Hopital Europeen Georges Pompidou (Hegp)
Paris, France
Hospital Saint Louis
Paris, France
Institut Gustave Roussy
Villejuif, France
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
Bari, Italy
L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi
Bologna, Italy
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Milan, Italy
Universita Campus Bio Medico Di Roma
Roma, Italy
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
Verona, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.